

REMARKS

As a result of the foregoing amendment, claims 1, 13 and 15 have been modified to delete the phrase "or derivatives thereof". Claim 11 has been amended to be dependant on claim 7 and thus obviate the formal rejection thereof. This rejection should be withdrawn.

Reconsideration and withdrawal of the rejection of claims 1,3,7,13,15,17,19,27,32 and 33 as being anticipated by the Frame et al article in Tetrahedron are requested. Inasmuch as the "derivative" language no longer appears in the claims, the breadth attributed to the claims in formulating the rejection is no longer applicable. Frame discloses only 5-amino-4-sulfonamidoimidazole nucleosides as potential inhibitors of purine nucleotide biosynthesis. The reference is devoid of any disclosure of fluorescent nucleotide as required by the present claims. Accordingly, the rejection of the claims as amended is no longer tenable and should be withdrawn.

In view the foregoing amendment, it is submitted that this application is now in condition for Allowance and favorable reconsideration and prompt notice of allowance are earnestly solicited.

Respectfully submitted,

Dated: February 9, 2006

By


Jules E. Goldberg

Reg. No. 24,408

REED SMITH LLP

599 Lexington Avenue

29th Floor

New York, NY 10022-7650

(212) 521-5400

Attorney for Applicant